At an information meeting organised between Alzheimer Europe and Nutricia, on 17 November 2020, the findings of the LipiDiDiet study, as well as its implications for clinical practice and future research, were presented to the members and staff of Alzheimer Europe. The meeting was well-attended with 22 participants in total, including the presenter Professor Tobias Hartmann and two representatives of Nutricia, Tomasz Rudka and Jovita Balcaitiene. 14 of Alzheimer Europe’s member organisations participated, alongside Alzheimer Europe staff members and Jean Georges, Executive Director.
Prof. Hartmann, Coordinator of the European Union funded LipiDiDiet / LipiDiet projects and trials delivered a presentation on the findings and on the role that medical nutrition could play in Alzheimer’s disease (AD). He also discussed the implications of the study for clinical practice and future research. Prof. Hartmann is the Director of the German Institute for Dementia Prevention (DIDP) and Chair of Experimental Neurology at the Saarland University Faculty of Medicine. He is a specialist on lipids and nutrition in AD and has published over 140 articles on AD.
Following the presentation section of the meeting, the floor was opened for a lively and interesting discussion. Questions from the audience were put to both Prof. Hartmann, and the representatives from Nutricia, providinga great opportunity for our members to understand the results of the study and its implications. The multinutrient intervention in the LipiDiDiet trial slowed decline on clinical and other measures related to cognition, function, brain atrophy, and disease progression. The results indicate that intervention benefits increased with long‐term use.
Read the results, here: https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.12172
